Workshop C: Antigen-Specific Targeting of Tumours Across MHC Barriers
Time: 3:00 pm
day: Workshop - Track A - Evening
Details:
- Looking beyond peptide antigens in tumour therapy
- The advantages of targeting oligomorphic antigen-presenting molecules
- The advantages of adoptive cell therapies based on MR1- restricted TCRs specific for tumour-associated metabolites, and CD1c-restricted TCRs specific for a leukaemia-associated lipid antigen
